Christopher J. Lord
802 works · 46,282 citations · h-index 99
Top works
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
- Resistance to therapy caused by intragenic deletion in BRCA2
- PARP inhibitors: Synthetic lethality in the clinic
- Rethinking ovarian cancer: recommendations for improving outcomes
- The DNA damage response and cancer therapy
- Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
- BRCAness revisited
- Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer
- Germline mutations in RAD51D confer susceptibility to ovarian cancer
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
- A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
- BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency
- Genetic Interactions in Cancer Progression and Treatment
- Utilizing RNA interference to enhance cancer drug discovery